99 related articles for article (PubMed ID: 12542669)
1. Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural sensitization.
Rubino T; Viganò D; Massi P; Parolaro D
Eur J Neurosci; 2003 Jan; 17(2):325-30. PubMed ID: 12542669
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
[TBL] [Abstract][Full Text] [Related]
3. Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen.
Corchero J; Romero J; Berrendero F; Fernandez-Ruiz J; Ramos JA; Fuentes JA; Manzanares J
Brain Res Mol Brain Res; 1999 Apr; 67(1):148-57. PubMed ID: 10101241
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice.
Romero J; Fernández-Ruiz JJ; Vela G; Ruiz-Gayo M; Fuentes JA; Ramos JA
Drug Alcohol Depend; 1998 May; 50(3):241-9. PubMed ID: 9649978
[TBL] [Abstract][Full Text] [Related]
5. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain.
Breivogel CS; Childers SR; Deadwyler SA; Hampson RE; Vogt LJ; Sim-Selley LJ
J Neurochem; 1999 Dec; 73(6):2447-59. PubMed ID: 10582605
[TBL] [Abstract][Full Text] [Related]
6. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
7. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Rubino T; Viganò D; Massi P; Parolaro D
J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
[TBL] [Abstract][Full Text] [Related]
8. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
9. Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum.
Sim LJ; Selley DE; Xiao R; Childers SR
Eur J Pharmacol; 1996 Jun; 307(1):97-105. PubMed ID: 8831110
[TBL] [Abstract][Full Text] [Related]
10. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.
Viganò D; Rubino T; Vaccani A; Bianchessi S; Marmorato P; Castiglioni C; Parolaro D
Psychopharmacology (Berl); 2005 Nov; 182(4):527-36. PubMed ID: 16079992
[TBL] [Abstract][Full Text] [Related]
12. Mu opioid receptor signaling in morphine sensitization.
Viganò D; Rubino T; Di Chiara G; Ascari I; Massi P; Parolaro D
Neuroscience; 2003; 117(4):921-9. PubMed ID: 12654343
[TBL] [Abstract][Full Text] [Related]
13. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions.
Rubino T; Vigano' D; Massi P; Spinello M; Zagato E; Giagnoni G; Parolaro D
Neuropharmacology; 2000 Apr; 39(7):1331-6. PubMed ID: 10760375
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.
Griffin G; Atkinson PJ; Showalter VM; Martin BR; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):553-60. PubMed ID: 9580597
[TBL] [Abstract][Full Text] [Related]
15. Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain.
Porcella A; Gessa GL; Pani L
Eur J Neurosci; 1998 May; 10(5):1743-51. PubMed ID: 9751146
[TBL] [Abstract][Full Text] [Related]
16. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
Eldeeb K; Leone-Kabler S; Howlett AC
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
[TBL] [Abstract][Full Text] [Related]
17. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.
Breivogel CS; Scates SM; Beletskaya IO; Lowery OB; Aceto MD; Martin BR
Eur J Pharmacol; 2003 Jan; 459(2-3):139-50. PubMed ID: 12524139
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid ligand-receptor signaling in the mouse uterus.
Das SK; Paria BC; Chakraborty I; Dey SK
Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
[TBL] [Abstract][Full Text] [Related]
19. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain.
Bidaut-Russell M; Devane WA; Howlett AC
J Neurochem; 1990 Jul; 55(1):21-6. PubMed ID: 2162376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
